NCT03460977 2026-03-13A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPfizerPhase 1 Recruiting453 enrolled
NCT04104776 2025-05-15A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartisPhase 1/2 Recruiting275 enrolled